btrx-246040
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2017 (NCT03193398)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Nociceptin receptorANTAGONIST
OPRL1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nn(-c2ncccc2CO)cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc12- Mol. weight
- 480.97 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3304244 ↗
Also known as
- btrx-246040
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06786637 | Phase 2 | Jun 30, 2025 | Mclean Hospital, National Institute of Mental Health (NIMH) |
| NCT05232032 | Phase 2 | Dec 1, 2022 | Brown University, Harvard University, Massachusetts Institute of Technology, Mclean Hospital, National Institute of Mental Health (NIMH), University of Washington |
| NCT03608371 | Phase 2 | Aug 31, 2018 | Neumora Therapeutics, Inc. |
| NCT03193398 | Phase 2 | Jun 12, 2017 | Neumora Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mclean Hospital | Academic/Hospital | 2 | 2 | 1 | 2022 |
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 1 | 2022 |
| Neumora Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2017 |
| Brown University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Massachusetts Institute of Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1